We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $50.71, marking a -2.59% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.04%. Elsewhere, the Dow saw a downswing of 0.57%, while the tech-heavy Nasdaq appreciated by 0.04%.
Shares of the company have appreciated by 9.44% over the course of the past month, outperforming the Medical sector's loss of 0.72%, and lagging the S&P 500's gain of 12.24%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. The company's upcoming EPS is projected at -$1.14, signifying a 27.85% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $8.39 million, showing a 864.14% escalation compared to the year-ago quarter.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.93 per share and revenue of $35.78 million. These results would represent year-over-year changes of +23.8% and +919.38%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 1.62% lower. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 147, this industry ranks in the bottom 40% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $50.71, marking a -2.59% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.04%. Elsewhere, the Dow saw a downswing of 0.57%, while the tech-heavy Nasdaq appreciated by 0.04%.
Shares of the company have appreciated by 9.44% over the course of the past month, outperforming the Medical sector's loss of 0.72%, and lagging the S&P 500's gain of 12.24%.
The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. The company's upcoming EPS is projected at -$1.14, signifying a 27.85% increase compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $8.39 million, showing a 864.14% escalation compared to the year-ago quarter.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.93 per share and revenue of $35.78 million. These results would represent year-over-year changes of +23.8% and +919.38%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 1.62% lower. CRISPR Therapeutics AG is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 147, this industry ranks in the bottom 40% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.